Je was op zoek naar: transient ischemic attack (Engels - Estisch)

transient ischemic attack (mini stroke)
mööduv isheemiline atakk (minirabandus),

transient ischemic attack, cerebral vascular accident
transitoorne isheemiline atakk, ajuveresoone lõhkemine

disturbance in attention, dysgeusia, impaired balance, hyperaesthesia, oral paraesthesia, transient ischemic attack
tähelepanuhäired, maitsehäire, tasakaaluhäired, liigärrituvus, oraalne paresteesia, transitoorne isheemiline atakk

agitation, anxiety disturbance in attention, dysgeusia, impaired balance, hyperaesthesia, oral paraesthesia, transient ischemic attack
diploopia, silmade punetus südamepekslemine

in clinical studies with pazopanib, myocardial infarction, ischemic stroke, and transient ischemic attack were observed (see section 4.8).
pasopaniibi kliinilistes uuringutes on täheldatud müokardiinfarkti, isheemilise insuldi ja transitoorse isheemilise ataki teket (vt lõik 4.8).

in the same clinical trials, cerebrovascular adverse events (cvae e.g., stroke, transient ischemic attack), including fatalities, were reported.
samades kliinilistes uuringutes täheldati ajuveresoonkonna kõrvaltoimeid (avkt, nt ajuinfarkt, transitoorne ajuisheemia), sh surmajuhtumeid.

this finding should be considered when prescribing raloxifene for postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation.
seda asjaolu peaks arvesse võtma raloksifeeni väljakirjutamisel postmenopausaalsetele naistele, kel on olnud insult või esinenud teised olulised insuldi riskifaktorid, nagu transientne isheemiline atakk või kodade fibrillatsioon.

this type of spontaneous recovery usually occurs following a type of stroke in which blood flow to the brain is temporarily interrupted but quickly restored, called a transient ischemic attack. in these circumstances, language abilities may return in a few hours or a few days.
seda tüüpi spontaanne taastumine toimub tavaliselt pärast liiki insult, kus verevoolu aju on ajutiselt katkestada, kuid kiiresti taastada, nimetatakse mööduv isheemiline atakk. sellises olukorras, keelealaste oskuste võib naasta mõne tunni või mõne päeva.

prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age
insuldi ja süsteemse emboolia (se) vältimine täiskasvanud, mittevalvulaarse kodade fibrillatsiooniga (nvaf) patsientidel, kel esineb vähemalt üks riskifaktoritest, nagu eelnev insult või transitoorne ajuisheemia (tia); vanus ≥ 75 aastat; südamepuudulikkus (new yorki südameassotsiatsiooni (nyha) ≥ 2.

in clinical studies with axitinib, arterial embolic and thrombotic events (including transient ischemic attack, myocardial infarction, cerebrovascular accident and retinal artery occlusion) were reported (see section 4.8).
aksitiniibi kliinilistes uuringutes on täheldatud arteriaalse emboolia ja tromboosi juhte (sealhulgas mööduv isheemiaatakk, müokardiinfarkt, ajuinsult ja silma võrkkesta arteri oklusioon) (vt lõik 4.8).

in the same study at 5 years, there was no increase in the risk of stroke including hemorrhagic, ischemic, embolic stroke, stroke type unspecified and transient ischemic attacks in fablyn-treated patients.
samas uuringus ei esinenud 5. aastal fablyn’iga ravitud patsientidel insuldi, sealhulgas hemorraagilise, isheemilise, emboolilise insuldi, teadmata tüüpi insuldi ja mööduvate isheemiliste hoogude riski suurenemist.

in monotherapy studies with axitinib (n = 850), arterial embolic and thrombotic adverse reactions (including transient ischemic attack, myocardial infarction, and cerebrovascular accident) were reported in 5.3% of patients receiving axitinib.
aksitiniibi monoteraapia uuringutes (n = 850) teatati 5,3%-l aksitiniibravi saavatest patsientidest kõrvaltoimena arteriaalse emboolia ja tromboosi juhtudest (sealhulgas mööduv isheemiline atakk, müokardiinfarkt ja ajuinsult).

an increased risk of arterial and venous thrombotic and thrombo-embolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using chcs, which are discussed in more detail in section 4.4.
khk-sid kasutavatel naistel on täheldatud suuremat riski arteriaalsete ja venoossete trombootiliste ja trombembooliliste sündmuste, sh müokardiinfarkti, insuldi, mööduvate isheemiliste atakkide, venoosse tromboosi ja kopsuemboolia tekkeks, mida on põhjalikumalt kirjeldatud lõigus 4.4.

patients who presented with cardiac events within 12 months prior to sunitinib administration, such as myocardial infarction (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic chf, cerebrovascular accident or transient ischemic attack, or pulmonary embolism were excluded from sunitinib clinical studies.
patsiendid, kellel esines 12 kuu jooksul enne sunitiniibi manustamist südamehaigust, näiteks müokardiinfarkti (sealhulgas tõsine/ebastabiilne stenokardia), koronaar-/perifeersete arterite šundilõikust, sümptomaatilist chfi, tserebrovaskulaarset haigust, transitoorset isheemilist atakki või kopsuembooliat, jäeti sunitiniibi kliinilisest uuringust välja.

29 immune system disorders drug hypersensitivity metabolism and nutrition disorders anorexia, polydipsia psychiatric disorders confusional state, listless, anorgasmia, blunted affect nervous system disorders unresponsive to stimuli, loss of consciousness, neuroleptic malignant syndrome, diabetic coma, cerebrovascular accident, depressed level of consciousness, cerebral ischemia, cerebrovascular disorder, transient ischemic attack, dysarthria, disturbance in attention, balance disorder, speech disorder, coordination abnormal, movement disorder eye disorders ocular hyperemia, eye discharge, eye swelling, dry eye, lacrimation increased, photophobia, visual acuity reduced, eye rolling, glaucoma ear and labyrinth disorders tinnitus vascular disorders flushing respiratory, thoracic, and mediastinal disorders wheezing, pneumonia aspiration, pulmonary congestion, respiratory disorder, rales, epistaxis, respiratory tract congestion, hyperventilation, dysphonia gastrointestinal disorders dysphagia, faecal incontinence, faecaloma, lip swelling, cheilitis skin and subcutaneous tissue disorders skin lesion, skin disorder, skin discoloration, seborrheic dermatitis, hyperkeratosis, dandruff, erythema musculoskeletal, connective tissue, and bone disorders rhabdomyolysis, joint swelling, posture abnormal, joint stiffness renal and urinary disorders enuresis, dysuria, pollakiuria reproductive system and breast disorders ejaculation disorder, vaginal discharge, menstrual disorder general disorders and administration site conditions generalised oedema, face oedema, gait disturbance, thirst, chills, peripheral coldness, drug withdrawal syndrome
Üldised häired ja manustamiskoha reaktsioonid generaliseerunud turse, näoturse, kõnnaku häired, janu, külmavärinad, käte- jalgade külmetuse tunne, ravimi võõrutusnähud.